GSK halts new clinical trials in Russia

pharmafile | March 18, 2022 | News story | Medical Communications  

Britain’s second biggest drugmaker, GlaxoSmithKline (GSK), has joined other pharmaceutical companies including Pfizer, sharing that it will not start clinical trials, or enroll new patients into studies, due to the invasion of Ukraine.

The pharmaceutical giant will continue to provide essential medicines to the country, and like others in the sector, will also continue with existing trials. The company has also shared that any profits made from operations in Russia will be used to support humanitarian relief efforts.

GSK had already stopped advertising its products in Russia, following the conflict. The company’s announcement follows similar moves by major US pharmaceutical giants, including Merck and Eli Lilly.

AstraZeneca, which is Britain’s largest pharmaceutical firm, continues to conduct clinical trials of new medicines in Russia and Ukraine. The company is evaluating whether to follow the lead of GSK, Pfizer, and Eli Lilly, and no longer begin new trials.

Sir Mene Pangolos, the Executive Vice-President of biopharmaceuticals research and development of AstraZeneca, has underlined that it is important to push ahead with clinical trials. He spoke to the Guardian: “The most important thing for us is to keep our employees safe and to make sure the supply of medicines to all these countries remains so people don’t get sick.” He underlined the importance of the trials for both patients and physicians.

GSK has commented: “We are providing targeted humanitarian support through long-term NGO partners who have teams on the ground in Ukraine and neighbouring countries.

“We’ll continue to respond as the situation evolves, guided by our humanitarian principles.”

GSK employs 1,100 people in Russia, and 400 in Ukraine.

Related Content

No items found

Latest content